ARTIVA BIOTHERAPEUTICS INC

Artiva Biotherapeutics’ CEO buys 425k shares, signaling confidence and potential upside amid rising immunotherapy pipeline.

Artiva Biotherapeutics CEO buys 45k shares amid insider confidence shift; investors should watch AlloNK/CAR‑NK trials for potential rally.

RA Capital’s recent buy of Artiva Biotherapeutics shares signals confidence in its NK‑cell platform and upcoming AlloNK launch—investors should watch the trend and option grant for potential upside.

Artiva Biotherapeutics insider buys 16,250 shares—director confidence signals growth potential for NK‑cell therapy pipeline and future earnings.

Artiva insiders boost shares, signaling confidence in late‑stage oncology pipeline and potential upside for investors.

Insightful view of Artiva’s insider trades: Subhashis Banerjee’s 10b5‑1 buys and sells reveal a disciplined, confidence‑driven rebalancing strategy, reinforcing investor optimism.

Artiva Biotherapeutics insider sales show routine RSU tax‑cover moves, not distress, but hint at short‑term supply pressure while execs stay long‑term invested.

Artiva Biotherapeutics insiders boost confidence with RSU and ESO grants, signaling strong support for its NK‑cell therapy pipeline and potential upside for investors.